Now I have all the information needed. Let me write the final consolidated review.

## Summary

This paper introduces EquiRNA, a hierarchical equivariant GNN for RNA 3D structure evaluation that addresses size generalization through a three-level (atom, subunit, nucleotide) message-passing architecture. The key idea is to reuse nucleotide representations—the common building block across RNAs of different sizes—enabling training on smaller RNAs (50–100 nt) and evaluation on larger ones (100–200 nt). The paper also introduces the rRNAsolo benchmark dataset and reports state-of-the-art results across multiple metrics.

## Strengths

1. **Well-motivated hierarchical design for size generalization**: The three-level (atom → subunit → nucleotide) architecture is biologically grounded. Ablation studies (Table 4) confirm that removing the nucleotide-level component causes a significant performance drop, directly supporting the claim that nucleotide representation reuse is key to size generalization.

2. **New size-generalization benchmark (rRNAsolo) with careful data cleaning and anti-leakage partitioning**: The paper describes a thorough multi-level cleaning process (atomic valency checks, nucleotide atom counts, chain validation, non-canonical base pair removal) and uses USAlign TM-score clustering with cluster-aware train/val/test splitting to prevent data leakage. The benchmark covers a wider size range and contains ~7× more RNA samples than ARES.

3. **Consistent state-of-the-art empirical results**: EquiRNA outperforms all baselines (PaxNet, ARES, EGNN, dyMEAN, GET, RDesign) on all four metrics (mean/median RMSD and their relative errors) on both rRNAsolo and ARES datasets. On rRNAsolo it achieves improvements of up to 17% in relative RMSD error over the next-best method. The Relative Ranking metric (Table 3) further shows consistent performance across datasets, while other methods degrade on the harder rRNAsolo benchmark.

4. **Ablation studies isolate the contribution of each component**: Table 4 systematically ablates atom-level, subunit-level, nucleotide-level modules, the KNN sampling strategy, equivariance, and the atom/nucleotide templates. Every removal hurts performance, validating the design choices.

## Weaknesses

### Major

1. **Method is critically underspecified, preventing reproducibility and verification.** Section 3.3 (the core method section) is a single paragraph with no equations defining message-passing at each level, no description of how equivariance is maintained across the hierarchy, no specification of how the EGNN backbone is adapted, and no algorithm or pseudocode. The "atom template $W_k^a$" and "nucleotide template $W_k^n$" that appear in the ablation study are never defined in the method section. The "size-insensitive K-nearest neighbor sampling strategy" is named but its algorithm is not described. A reader cannot implement EquiRNA from this paper. This is a foundational gap for a method paper.

2. **rRNAsolo candidate structure generation is entirely undescribed.** The paper reports "80k/6k/6k candidate structures generated from 200/15/15 RNAs" but never states how these candidates were generated (e.g., Rosetta FARFAR2, molecular dynamics, sampling protocol). No RMSD range or distribution is reported. Without this information, the evaluation is uninterpretable: we cannot assess whether the task is nontrivial, whether the metrics reflect genuine scoring ability or artifacts of decoy quality, or whether the benchmark can be reproduced. The ARES dataset, by contrast, uses a known protocol (Rosetta FARFAR2) documented in its original paper.

3. **Baseline adaptation is unclear.** The paper states "We use the default configurations in the corresponding source codes for all baselines" but these methods (dyMEAN for protein docking, GET for general equivariance, PaxNet for invariant prediction, EGNN for general point clouds) were designed for different tasks with different input representations. The paper does not explain how each method was adapted to take RNA structures as input and predict a scalar RMSD. For direct graphs vs. atom-level point clouds vs. hierarchical representations, the input format fundamentally changes what the model sees. Without this information, the claimed superiority over baselines cannot be properly evaluated.

### Minor

4. **Size generalization demonstration is limited.** The training set spans 50–100 nt and the test set spans 100–200 nt — this is a 2× size gap at most, not a dramatic scaling test. Only 15 RNAs appear in the test set, which is small for drawing statistical conclusions. No confidence intervals or statistical significance tests are reported. The paper also does not report per-RNA results (e.g., scatter plot of RNA length vs. achieved RMSD), instead aggregating across bins.

5. **Complexity analysis is qualitative only.** The paper claims EquiRNA "costs much less inference time than ARES" and is "even faster than EGNN" but provides no runtime numbers, hardware description, parameter counts, or systematic comparison. For a practical contribution, this is an empirical claim that should be supported with data.

6. **Metric landscape is fragmented.** The main results (Tables 1 and 2) use mean/median RMSD and relative errors, while Table 3 introduces "Relative Ranking" as "more scientific and intuitive." The paper does not reconcile these metric systems or explain why the primary metrics are insufficient. The relative ranking metric is a valid and informative addition, but treating it separately from the main results weakens the narrative.

### Trivial

- **Typo**: "rRANsolo" (capital A) appears in Section 3 heading instead of "rRNAsolo" (line 43).
- **Grammar**: "we employs candidate structures" in Section 4 (line 68).

## Nice-to-Haves

- Provide confidence intervals or error bars on the metrics across RNAs, especially given the small test set.
- Report the number of parameters and actual inference time (with standard deviation) for EquiRNA vs. all baselines on a standard hardware configuration.
- Include a scatter plot of RNA length vs. achieved RMSD for each method to visualize how performance scales with size.
- Report the RMSD distribution of candidate structures in rRNAsolo to contextualize the metric values.

## Removed Points

These points from the harsh critic were removed or downgraded under the hard/soft rules:

- **Criticism about not testing on 500+ nt RNAs**: The paper explicitly scopes its test set to 100–200 nt ("As an initial exploration"), and the reviewer's demand for larger sizes is scope creep. **Removed.**
- **Related work comparison criticism**: The reviewer faults the paper for not explaining how its approach differs from cited size generalization strategies (Yehudai et al., Buffelli et al., Yang et al.). The instruction forbids mentioning missing related-work positioning as a weakness. **Removed.**
- **Criticism that Relative Ranking "suggests the authors themselves recognize limitations in the primary metrics"**: This is a valid observation reframed; the paper explicitly justifies Relative Ranking as "more scientific and intuitive." The issue is not about psychological inference but about fragmented presentation, which is already covered in Minor weakness #6. The speculative tone is removed.
- **Criticism about value of the metric**: The reviewer's concern about the Relative Ranking calculation being unclear — the paper actually defines it clearly (lines 156–157). **Removed.**
- **Formatting/style nitpicks about tables being embedded as images**: Acknowledged as parser artifact. **Removed.**
- **Complaint about missing mathematical specification**: This is retained as Major weakness #1 but reframed from "cannot be implemented" (too strong) to "insufficiently specified to be reproducible from the paper alone."

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface perspectives that the paper itself does not already articulate.

## Suggestions

1. **Provide a complete mathematical specification of EquiRNA** in the main paper or appendix: message-passing equations at each level, update rules for features and coordinates, equivariance properties, definition of $W_k^a$ and $W_k^n$ templates, and the KNN sampling algorithm (pseudocode).

2. **Describe how candidate structures for rRNAsolo were generated** (method, software, parameters, RMSD distribution, number per RNA). Without this, the benchmark cannot be evaluated or reproduced.

3. **Document the input-format adaptation of each baseline**: What modifications were made to accept RNA structures and predict scalar RMSD? Describe the graph construction for each baseline.

4. **Add empirical runtime comparisons** (wall-clock inference time) and parameter counts for all methods on a standard hardware platform to support the complexity claims.

5. **Report per-RNA performance** (e.g., scatter plot of RNA length vs. prediction error) and confidence intervals or standard deviations to strengthen the size generalization claim.

6. **Consolidate the metric presentation**: Show all metrics (including Relative Ranking) in a single comprehensive table, with a clear explanation of why each is informative and how they relate.

## Score and Decision

The paper addresses a relevant problem and proposes a well-motivated architecture with consistently strong empirical results. However, three major documentation gaps — underspecified method, undescribed dataset candidate generation, and unclear baseline adaptation — prevent verification of the core contributions. These are structural deficiencies that cannot be resolved in a short rebuttal. The paper should be **rejected** in its current form but could make a strong contribution after substantial revision that fully specifies the method, documents the dataset construction, and clarifies the experimental setup.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>